Low-dose growth hormone for 40 weeks induces HIV-1-specific T cell responses in patients on effective combination anti-retroviral therapy

Clinical and Experimental Immunology

Volumn 173, Issue 3, 2013, Pages 444-453

  Herasimtschuk, A A ^a   Hansen, B R ^c   Langkilde, A ^c   Moyle, G J ^b   Andersen, O ^c   Imami, N ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^c Mental Health Center Glostrup   (Denmark)

Author keywords

Immune activation; Immune based therapy; Recombinant human growth hormone; T cells

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; GAMMA INTERFERON; HUMAN GROWTH HORMONE; PLACEBO; T LYMPHOCYTE RECEPTOR;

ADULT; APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL POPULATION; CELL SPECIFICITY; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MALE; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE; TREATMENT DURATION;

IMMUNE ACTIVATION; IMMUNE-BASED THERAPY; RECOMBINANT HUMAN GROWTH HORMONE; T CELLS;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV INFECTIONS; HIV-1; HUMAN GROWTH HORMONE; HUMANS; IMMUNOPHENOTYPING; INTERFERON-GAMMA; MALE; MIDDLE AGED; PEPTIDES; PHENOTYPE; T-LYMPHOCYTE SUBSETS; THYMUS GLAND; VIRAL LOAD;

EID: 84881500199     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12141     Document Type: Article

References (38)

1. Cominelli S, Raguso CA, Karsegard L etal. Weight-losing HIV-infected patients on recombinant human growth hormone for 12 wk: a national study. Nutrition 2002; 18:583-586.
2. Napolitano LA, Lo JC, Gotway MB etal. Increased thymic mass and circulating naive CD4 T cells in HIV-1-infected adults treated with growth hormone. AIDS 2002; 16:1103-1111.
3. Moyle GJ, Daar ES, Gertner JM etal. Growth hormone improves lean body mass, physical performance, and quality of life in subjects with HIV-associated weight loss or wasting on highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2004; 35:367-375.
4. Pires A, Pido-Lopez J, Moyle G, Gazzard B, Gotch F, Imami N. Enhanced T-cell maturation, differentiation and function in HIV-1-infected individuals after growth hormone and highly active antiretroviral therapy. Antivir Ther 2004; 9:67-75.
5. Herasimtschuk AA, Westrop SJ, Moyle GJ, Downey JS, Imami N. Effects of recombinant human growth hormone on HIV-1-specific T-cell responses, thymic output and proviral DNA in patients on HAART: 48-week follow-up. J Immune Based Ther Vaccines 2008; 6:7.
6. Napolitano LA, Schmidt D, Gotway MB etal. Growth hormone enhances thymic function in HIV-1-infected adults. J Clin Invest 2008; 118:1085-1098.
7. Lo J, You SM, Canavan B etal. Low-dose physiological growth hormone in patients with HIV and abdominal fat accumulation: a randomized controlled trial. JAMA 2008; 300:509-519.
8. Grunfeld C, Thompson M, Brown SJ etal. Recombinant human growth hormone to treat HIV-associated adipose redistribution syndrome: 12-week induction and 24-week maintenance therapy. J Acquir Immune Defic Syndr 2007; 45:286-297.
9. Hansen BR, Kolte L, Haugaard SB etal. Improved thymic index, density and output in HIV-infected patients following low-dose growth hormone therapy: a placebo controlled study. AIDS 2009; 23:2123-2131.
10. Smith K, Zheng L, Bosch R etal. Treatment with recombinant growth hormone is associated with modest improvement in CD4 lymphocyte reconstitution in HIV-infected persons on antiretroviral therapy: results of ACTG A5174. AIDS Res Hum Retroviruses 2010; 26:425-432.
11. Guihot A, Bourgarit A, Carcelain G, Autran B. Immune reconstitution after a decade of combined antiretroviral therapies for human immunodeficiency virus. Trends Immunol 2011; 32:131-137.
12. Kaufmann GR, Elzi L, Weber R etal. Interruptions of cART limits CD4 T-cell recovery and increases the risk for opportunistic complications and death. AIDS 2011; 25:441-451.
13. Welniak LA, Sun R, Murphy WJ. The role of growth hormone in T-cell development and reconstitution. J Leukoc Biol 2002; 71:381-387.
14. Rietschel P, Hadigan C, Corcoran C etal. Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy. J Clin Endocrinol Metab 2001; 86:504-510.
15. Vigano A, Mora S, Brambilla P etal. Impaired growth hormone secretion correlates with visceral adiposity in highly active antiretroviral treated HIV-infected adolescents. AIDS 2003; 17:1435-1441.
16. Gelato M, McNurlan M, Freedland E. Role of recombinant human growth hormone in HIV-associated wasting and cachexia: pathophysiology and rationale for treatment. Clin Ther 2007; 29:2269-2288.
17. Sivakumar T, Mechanic O, Fehmie DA, Paul B. Growth hormone axis treatments for HIV-associated lipodystrophy: a systematic review of placebo-controlled trials. HIV Med 2011; 12:453-462.
18. - natural killer (NK) cell subset and NK cell interferon-gamma production during antiretroviral therapy for HIV-1: partial recovery by human growth hormone. Clin Exp Immunol 2003; 134:470-476.
19. Carr A, Emery S, Law M, Puls R, Lundgren JD, Powderly WG. An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet 2003; 361:726-735.
20. Imami N, Hardy GA, Nelson MR etal. Induction of HIV-1-specific T cell responses by administration of cytokines in late-stage patients receiving highly active anti-retroviral therapy. Clin Exp Immunol 1999; 118:78-86.
21. Hardy GA, Imami N, Nelson MR etal. A phase I, randomized study of combined IL-2 and therapeutic immunisation with antiretroviral therapy. J Immune Based Ther Vaccines 2007; 5:6.
22. Hunt PW, Deeks SG. Immune-based therapy for HIV infection: are acute and chronic HIV infection different diseases? J Infect Dis 2006; 194:1632-1634.
23. Hazenberg MD, Otto SA, van Benthem BH etal. Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS 2003; 17:1881-1888.
24. Bartovska Z, Beran O, Rozsypal H, Holub M. Antiretroviral treatment of HIV infection does not influence HIV-specific immunity but has an impact on non-specific immune activation. Curr HIV Res 2011; 9:88-94.
25. Douek DC, Roederer M, Koup RA. Emerging concepts in the immunopathogenesis of AIDS. Annu Rev Med 2009; 60:471-484.
26. Downey JS, Imami N. T-cell dysfunction in HIV-1 infection: targeting the inhibitors. HIV Ther 2010; 4:83-99.
27. Betts MR, Ambrozak DR, Douek DC etal. Analysis of total human immunodeficiency virus (HIV)-specific CD4(+) and CD8(+) T-cell responses: relationship to viral load in untreated HIV infection. J Virol 2001; 75:11983-11991.
28. Maecker HT, Dunn HS, Suni MA etal. Use of overlapping peptide mixtures as antigens for cytokine flow cytometry. J Immunol Methods 2001; 255:27-40.
29. Stanley TL, Grinspoon SK. GH/GHRH axis in HIV lipodystrophy. Pituitary 2009; 12:143-152.
30. Franco JM, Rubio A, Martinez-Moya M etal. T-cell repopulation and thymic volume in HIV-1-infected adult patients after highly active antiretroviral therapy. Blood 2002; 99:3702-3706.
31. Kotler DP, Muurahainen N, Grunfeld C etal. Effects of growth hormone on abnormal visceral adipose tissue accumulation and dyslipidemia in HIV-infected patients. J Acquir Immune Defic Syndr 2004; 35:239-252.
32. Lo J, You SM, Liebau J, Lee H, Grinspoon S. Effects of low-dose growth hormone withdrawal in patients with HIV. JAMA 2010; 304:272-274.
33. Clark R. The somatogenic hormones and insulin-like growth factor-1: stimulators of lymphopoiesis and immune function. Endocr Rev 1997; 18:157-179.
34. Rao MN, Mulligan K, Tai V etal. Effects of insulin-like growth factor (IGF)-I/IGF-binding protein-3 treatment on glucose metabolism and fat distribution in human immunodeficiency virus-infected patients with abdominal obesity and insulin resistance. J Clin Endocrinol Metab 2010; 95:4361-4366.
35. Falutz J, Mamputu JC, Potvin D etal. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab 2010; 95:4291-4304.
36. Richman DD, Margolis DM, Delaney M, Greene WC, Hazuda D, Pomerantz RJ. The challenge of finding a cure for HIV infection. Science 2009; 323:1304-1307.
37. Deeks SG, Autran B, Berkhout B etal. Towards an HIV cure: a global scientific strategy. Nat Rev Immunol 2012; 12:607-614.
38. Rosenfeld RG, Cohen P, Robison LL etal. Long-term surveillance of growth hormone therapy. J Clin Endocrinol Metab 2012; 97:68-72.